Document Detail


Diabetic dyslipidemia: extending the target beyond LDL cholesterol.
MedLine Citation:
PMID:  20489416     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Lowering low-density lipoprotein cholesterol plays an important role in therapeutic strategies designed to reduce cardiovascular risk. However, the residual clinical risk in statin trials suggests that additional therapies will be required to achieve more effective prevention of cardiovascular disease. The high prevalence of hypertriglyceridemia and low levels of high-density lipoprotein cholesterol in diabetes presents further targets for the development of new cardioprotective therapies.
Authors:
Stephen J Nicholls; Pia Lundman; Jean-Claude Tardif
Related Documents :
16325036 - Stabilization of carotid atheroma assessed by quantitative ultrasound analysis in nonhy...
17901546 - Plasma 24s hydroxycholesterol response to statins in alzheimer's disease patients: effe...
19552506 - Update on patented cholesterol absorption inhibitors.
17142146 - Lipoprotein effects of combined ezetimibe and colesevelam hydrochloride versus ezetimib...
1402476 - Effect of vegetable oil intake on erythrocyte physical properties and hemorheology.
18495466 - Carbohydrate restriction and dietary cholesterol distinctly affect plasma lipids and li...
Publication Detail:
Type:  Journal Article; Review    
Journal Detail:
Title:  European journal of cardiovascular prevention and rehabilitation : official journal of the European Society of Cardiology, Working Groups on Epidemiology & Prevention and Cardiac Rehabilitation and Exercise Physiology     Volume:  17 Suppl 1     ISSN:  1741-8275     ISO Abbreviation:  Eur J Cardiovasc Prev Rehabil     Publication Date:  2010 May 
Date Detail:
Created Date:  2010-05-21     Completed Date:  2010-08-30     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  101192000     Medline TA:  Eur J Cardiovasc Prev Rehabil     Country:  England    
Other Details:
Languages:  eng     Pagination:  S20-4     Citation Subset:  IM    
Affiliation:
Department of Cardiovascular Medicine, Cleveland Clinic, Cleveland, OH 44195, USA. nichols1@ccf.org
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Antilipemic Agents / therapeutic use*
Biological Markers / blood
Cardiovascular Diseases / blood,  etiology,  prevention & control*
Cholesterol, HDL / blood
Cholesterol, LDL / blood*
Diabetes Complications / blood,  drug therapy*,  etiology
Diabetes Mellitus, Type 2 / blood,  complications,  drug therapy*
Dyslipidemias / blood,  drug therapy*,  etiology
Humans
Treatment Outcome
Triglycerides / blood
Chemical
Reg. No./Substance:
0/Antilipemic Agents; 0/Biological Markers; 0/Cholesterol, HDL; 0/Cholesterol, LDL; 0/Triglycerides

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Hyperglycaemia and the vessel wall: the pathophysiological aspects on the atherosclerotic burden in ...
Next Document:  Glucose lowering and cardiovascular disease: what do we know and what should we do?